Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India.
Metrics to compare | SPRL | Peers Peers - average of corresponding metrics from companies closely matching SPRL: SMSPHARMA, ALIVUS, MOREPENLAB, ANUHPHR, SHILPAMED | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRLPeersSector |
---|---|---|---|---|
P/E Ratio | 29.3x | 31.2x | −0.5x | |
PEG Ratio | 0.51 | 0.80 | 0.00 | |
Price/Book | 5.5x | 3.6x | 2.6x | |
Price / LTM Sales | 7.9x | 3.6x | 3.2x | |
Upside (Analyst Target) | 23.4% | 7.2% | 41.7% | |
Fair Value Upside | Unlock | −4.1% | 6.1% | Unlock |